(VIANEWS) – Shares of TherapeuticsMD (NASDAQ: TXMD) slid by a staggering 27.71% in 21 sessions from $6.17 at 2022-11-10, to $4.46 at 19:44 EST on Friday, following the last session’s upward trend. NASDAQ is falling 0.52% to $11,226.36, following the last session’s downward trend.

TherapeuticsMD’s last close was $4.46, 88.42% below its 52-week high of $38.50.

About TherapeuticsMD

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Earnings per Share

TherapeuticsMD’s trailing 12 months profit per share is $-0.666

Annual Top and Bottom Value

TherapeuticsMD stock was valued at $4.46 as of 19:44 EST. This is way lower than the 52-week high at $38.50, and much higher than its 52 week low at $1.99.

Moving Average

TherapeuticsMD’s worth is way below its 50-day moving average of $7.15 and way under its 200-day moving average of $10.00.

Volume

TherapeuticsMD’s current reported volume is currently 36956, which is 49.04% lower than its average volume (71804).

Sales Growth

TherapeuticsMD saw a 8.6% increase in sales for its current quarter, and 3.6% the following.

More news about TherapeuticsMD (TXMD).